Background-Sirolimus-eluting stent (SES) implantation aggravated endothelial vasomotor dysfunction in infarct-related coronary arteries. Methods and Results-This study examined the effect of SES implantation on the duration of reperfusion-induced endothelial vasomotor dysfunction in infarct-related coronary arteries and on postinfarct left ventricular dysfunction in acute myocardial infarction (AMI). Patients with a first AMI due to occlusion of the left anterior descending coronary artery and successful reperfusion using SES (nϭ15) or bare metal stents (BMS; nϭ18) were examined. The vasomotor response of the left anterior descending coronary artery to acetylcholine and left ventriculography were examined 2 weeks and 6 months after AMI. At 6 months after AMI, the impairment of epicardial coronary artery dilation and coronary blood flow increase in response to acetylcholine was recovered from 2 weeks after AMI in BMS-treated patients, whereas the responses of SES-treated patients improved but remained impaired compared with BMS-treated patients (% increase in blood flow, 77Ϯ12% in SES versus 116Ϯ15% in BMS at 10 g/min of acetylcholine, PϽ0.01). Left ventricular regional wall dysfunction in the left anterior descending coronary artery territory improved from 2 weeks to 6 months after AMI in BMS-treated patients but not in SES-treated patients (% improvement of average SD/chord, 6% in SES versus 19% in BMS, PϽ0.05), although left ventricular global ejection fraction was similar between the groups at any time points. Conclusions-SES implantation may delay recovery of reperfusion-induced endothelial vasomotor dysfunction in infarct-related coronary arteries and left ventricular regional dysfunction for at least 6 months after AMI. (Circ Cardiovasc Intervent. 2009;2:384-391.)
ndothelial injury has occurred in the entire vascular tree of the infarct-related coronary artery after ischemiareperfusion in acute myocardial infarction (AMI). 1, 2 Endothelial damage incurred during reperfusion injury may limit the restoration of blood flow to potentially viable ischemic myocardium, which importantly contributes to infarct extension and poor prognosis after AMI. 3, 4 However, it has been shown that coronary endothelial vasomotor dysfunction can be reversed in association with improvement of left ventricular (LV) dysfunction during the chronic phase of MI. 5, 6 Clinical Perspective on p 391
Despite the beneficial clinical effects of drug-eluting stents (DES), [7] [8] [9] the delayed endothelialization with DES implantation raises concern about complications of stent thrombosis and coronary spasm. 10 -14 We have previously reported that sirolimus-eluting stent (SES) implantation aggravates endothelium-dependent vasomotor dysfunction in resistance and large vessels of the infarct-related coronary arteries during the early course of AMI. 15 However, the time course of reperfusion-induced endothelial dysfunction in SES-treated coronary arteries is unknown. Thus, this study examined the effect of SES implantation on the duration of reperfusioninduced endothelial dysfunction in infarct-related coronary arteries and on postinfarct LV dysfunction.
descending coronary artery (LAD), who were admitted within 12 hours of symptom onset to Yamanashi University Hospital between January 2004 and April 2007. Diagnosis of AMI was based on the presence of all of the following criteria: typical chest pain persisting for Ն30 minutes, ST-segment elevation of Ͼ0.2 mV in Ն2 contiguous leads on the standard 12-lead ECG, and elevation of serum creatine kinase levels to more than twice the upper limit of normal. All of the study patients received emergent coronary angiography and successful reperfusion therapy by primary percutaneous coronary intervention using SES (nϭ16) or bare metal stents (BMS; nϭ24) after balloon coronary angioplasty. Because SES did not become available in Japan until August 2004, all patients treated before this date received BMS. Because clopidogrel was not available until May 2006 in Japan, SES were used only in patients who were confirmed to have no side effects from the previous use of ticlopidine, and BMS was used in the remaining patients. The exclusion criteria were as follows: (1) organic stenosis Ն30% in the LAD at 2 weeks and 6 months after AMI; (2) percutaneous coronary intervention at multiple segments of the LAD; (3) in-stent and peri-stent restenosis (Ͼ30% diameter stenosis) at the 6 month study after AMI; (4) previous percutaneous coronary intervention in the LAD before AMI; (5) previous coronary artery bypass surgery before AMI; (6) cardiovascular events during 6 months after AMI; (7) congestive heart failure; (8) persistent atrial fibrillation or a paced rhythm; (9) presence of collaterals to the LAD with Rentrop grade Ն2; (10) coronary artery spasm in the LAD in response to the intracoronary infusion of acetylcholine 15, 16 ; and (11) valvular heart diseases, secondary hypertension, stroke, renal dysfunction (serum creatinine concentration Ͼ2.0 mg/dL) or other serious diseases. This study also included 16 control subjects who were selected from 72 consecutive subjects with normal coronary angiograms and left ventriculograms to match the age, sex, and other traditional risk factors of the AMI patients (Table 1) . These control subjects served as a reference group for the coronary vasomotor responses, LV function, and plasma concentrations of vascular endothelial growth factor (VEGF), tumor necrosis factor-␣ (TNF␣), and monocyte chemoattractant protein-1 (MCP-1). Written informed consent was obtained from all patients before the study. The study was in agreement with the guidelines approved by the ethics committee at Yamanashi University Hospital.
Study Protocol and Assays
Cardiac catheterization including coronary vasomotor function test and left ventriculography was performed twice at 2 weeks and 6 months after AMI. Blood sampling from the anterior interventricular vein (AIV) and the aortic root (AO) was repeatedly performed at the cardiac catheterization before systemic heparinization, as described in our previous report. 15 Also, the measurement of coronary vasomotor response, left ventriculography, and blood sampling were performed only once in all of the control subjects. Enzyme-linked immunosorbent assay with commercially available kits were used for measurement of plasma levels of free VEGF 15 (R&D Systems, Minneapolis, Minn), TNF␣ (R&D Systems), and MCP-1 (Bender MedSystems, GmbH, Vienna, Austria). These cytokines were selected because these are known to be upregulated in ischemic ventricle and play a role in pathogenesis of damaged vessels and ischemic myocardium after AMI. All lipid-lowering drugs and vasodilators were withdrawn more than 3 days before coronary angiography in patients with AMI and control subjects.
Quantitative Coronary Angiography and Coronary Blood Flow Measurement
After the blood sampling, a quantitative coronary angiographic study was performed as in our previous reports. 15, 16 A 6F Judkins catheter was introduced into the left main coronary artery, and all drugs were infused directly into the left main coronary artery through the Judkins catheter at infusion rates of 2 mL/min. After baseline angiography, incremental doses of acetylcholine (5, 10, and 50 g/min) were infused directly into the left main coronary artery through the Judkins catheter for 2 minutes with a 5-minute interval between the 2 doses. After an additional 15 minutes, intracoronary sodium nitroprusside (10 g/min) was infused in the same manner as acetylcholine. After another 15 minutes, intracoronary isosorbide dinitrate (1 mg) was administered. Coronary angiography was repeated before and at the end of each infusion.
Luminal diameter in a segment 15 to 25 mm from the distal edge of the stent in the LAD was measured before and at each infusion quantitatively (Cardio 500, Kontron Instruments, Munich, Germany). 15 Each segment was referenced to a specific anatomic landmark for identification, and angiograms at 2 weeks and 6 months after AMI were examined in parallel to ensure analysis of the identical portion of the vessel. Luminal diameter at the mid segments of LAD was measured in all of the control subjects in the same manner as in the AMI patients.
Blood flow velocity was measured before and at each infusion using a 0.014-inch wire equipped with a Doppler crystal at its tip (FloWire, Cardiometrics, Mountain View, Calif). The wire was carefully advanced through the Judkins catheter, and the wire tip was positioned in a segment of the LAD 5 to 15 mm from the distal edge of the stent. 15 For calculating flow, coronary luminal diameter was also measured in a segment of the LAD 3 to 8 mm distal to the tip of the flow wire before and at each infusion in addition to measurement of coronary luminal diameter in a segment 15 to 25 mm from the distal edge of the stent in the LAD. Coronary blood flow (mL/min) was estimated from coronary blood flow velocity and luminal diameter by the following formula: 0.5ϫaveraged peak velocity (cm/min)ϫcross-sectional area (cm 2 ), as described previously. 15 Responses of the coronary artery diameter and coronary blood flow to infusions of acetylcholine, sodium nitroprusside, and nitrates were expressed as a percent changes from baseline values taken just before each infusion. These measurements were performed by 2 observers (Y.W. and K. W.) blinded to the study protocol and patients' clinical characteristics. Measurements of the percent changes in coronary diameter and coronary blood flow in response to acetylcholine (10 g/min) from the respective baseline values by the 2 independent observers were highly reproducible (rϭ0.99 and 0.98; mean difference, 0.81Ϯ0.04% and 2.4Ϯ0.3%, respectively).
Analysis of the Left Ventriculogram
LV ejection fraction was determined with left ventriculograms by area-length methods using computer-assisted analysis (Cardio 2000; Fukuda-Denshi Corporation, Tokyo, Japan). The centerline method was used for quantification of regional wall motion (Cardio 2000; Fukuda-Denshi Corporation). 17 The severity of the regional wall motion abnormality was expressed as the average SD from the mean wall motion of normal subjects per chord (SD/Chord) within the LAD territory using digitized left ventriculography in the 30-degree right anterior oblique projection. 17 The reduction of regional wall motion in the infarct-related area yielded approximately Ϫ1 to Ϫ4 SD/Chord. 17 These measurements were performed by 2 independent observers (T. K. and T. Y.) blinded to the study protocol and patients' clinical characteristics. Measurements of SD/Chord by the 2 observers were highly reproducible (rϭ0.99; mean difference, 2.3Ϯ1.2%).
Statistical Analysis
Data are expressed as the meanϮSD or percentage of the patients otherwise indicated. The frequencies between 2 groups of patients and the means between 2 groups were compared using a 2 test and a Student's paired or unpaired t test, respectively. When more than 2 groups were compared, a one-way analysis of variance was performed followed by a Sheffe test for post hoc comparison of group means. The mean values of coronary vasomotor responses and other parameters between the 2 patient groups were compared using two-way analysis of variance for repeated measures followed by post hoc testing with a Sheffe test. When frequencies among the patients
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with SES, those with BMS, and control subjects were compared, a 2 test using a 2ϫ3 contingency table was initially examined for independence of frequencies among the 3 groups. When independence was significant by a 2 test, the wholly significant difference was calculated between the 2 groups. A confidence level of PϽ0.05 was considered statistically significant. Analyses were performed with StatView 5.0 (SAS Institute, Cary, NC) and STATA version 10.0 (Stata Corp, College Station, Tex).
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Results

Patient Characteristics and Outcomes During 6 Months After AMI
Of the 40 patients who were enrolled at the 2-week study after AMI, 4 patients (1 SES patient and 3 BMS patients) had target lesion revascularization due to peristent or in-stent restenosis (ISR) at the 6-month study after AMI. All 4 patients with target lesion revascularization had Ն75% angiographic diameter stenosis in the stented lesions of the LAD in spite of absence of the symptoms and the objective signs of myocardial ischemia. Moreover, the other 3 patients (all BMS patients) had moderate angiographic restenosis (Ͻ75% and Ն30%) in the stented lesion at the 6-month study. These 7 patients with restenosis (1 SES patient and 6 BMS patients) were excluded for coronary vasomotor function test at 6 months after AMI because even moderate stenosis (Ն30%) in the conduit coronary artery may affect an increase in coronary blood flow. No patient had major cardiovascular events during the 6 months after AMI. The remaining 33 patients (15 SES patients and 18 BMS patients) completed the study protocol. Their clinical characteristics are shown in Table  1 . The profiles of the coronary risk factors were similar among the AMI patients treated with SES and BMS at both 2 weeks and 6 months after AMI and control subjects ( Table 1) . Frequencies of cardiac medication usage at either 2 weeks or 6 months after AMI, clinical parameters associated with AMI, and variables related to the coronary intervention were comparable between patients with SES and BMS (Tables 1 and 2 ). The use of ␤-blocker is not frequent in Japan because ␤-blocker treatment may have a risk of provocation of coronary artery spasm that is highly prevalent in Japan. 16 Intravascular ultrasound showed no dissection of the LAD in either the SES or BMS group at 2 weeks and 6 months after AMI (data not shown), but minimal luminal diameter in the stented segment was smaller in the BMS group than in the SES group at 6 months after AMI (Table 2) .
Epicardial Coronary Vasomotion and Coronary Blood Flow
The epicardial diameters and the coronary blood flow in the LAD at rest were similar between the SES-and BMS-treated patients at either 2 weeks or 6 months after AMI, and these parameters at rest were unchanged from 2 weeks to 6 months after AMI in both treatment groups (Table 1 and supplemental Table I ). Flow velocity values, absolute coronary diameters for coronary blood flow and calculated coronary blood flow at rest and in response to acetylcholine are shown in the supplemental Table I . At 2 weeks after AMI, the coronary dilation and blood flow increase in response to acetylcholine were impaired in the SES-treated patients and the BMS-treated patients compared with control subjects (Figure 1) . And, the LAD of the SES-treated patients had greater impairment of the coronary responses to acetylcholine than the LAD of the BMS-treated patients (Figure 1 ). At 6 months, the responses of the LAD epicardial diameter and blood flow to acetylcholine in the BMS-treated patients had recovered to levels similar to those of the control subjects ( Figure 1 ). In contrast, the LAD responses of the SES-treated patients were also improved at 6 months, but remained lower compared with the BMS-treated patients (Figure 1 ). Vasomotor responses to nitrates and sodium nitroprusside of the LAD were similar among control subjects, SES-and BMS-treated patients at 2 weeks and 6 months ( Figure 2 ).
LV Function
Left ventriculography was performed at 2 weeks and 6 months after AMI in all of the initially enrolled 40 patients including those with ISR and/or target lesion revascularization. Clinical characteristics of these patients (supplemental Tables II and III) were similar to those of the 33 patients without ISR and target lesion revascularization. At 2 weeks after AMI, LV regional wall motion in the LAD territory was impaired in both the SES-and BMS-treated patients compared with the control subjects, and this impairment was comparable between the 2 treatment groups ( Figure 3A) . At 6 months, LV regional wall motion was significantly improved in the BMS-treated but not the SES-treated patients ( Figure  3A ). LV regional wall motion at 6 months was better in the BMS-treated patients than the SES-treated patients when patients with restenosis were excluded ( Figure 3A , left panel), whereas it was not significantly different between the 2 treatment groups when patients with restenosis were included ( Figure 3A , right panel). Global LV ejection fraction was not significantly different between the SES-and BMStreated patients at either 2 weeks or 6 months, and it was unchanged from 2 weeks to 6 months after AMI in both treatment groups ( Figure 3B ).
Levels of VEGF, TNF␣, and MCP-1
The AO levels of VEGF and TNF␣ but not MCP-1 at 2 weeks were significantly higher in both the SES-and BMS-treated patients compared with levels in the control subjects; however, levels of VEGF and TNF␣ at 6 months in both treatment groups were decreased to levels similar to those in the control subjects (Table 1 ). There was a significant step-down of VEGF levels from AO to AIV in the SES-treated patients at 2 weeks but not at 6 months after AMI (Table 1 ). There was no significant difference in VEGF levels between the AO and AIV in the BMS-treated patients at 2 weeks and 6 months after AMI. There was no significant difference in TNF␣ and MCP-1 levels between the AO and AIV in both the SES-and BMS-treated patients at 2 weeks and 6 months after AMI ( Table 1) .
Relationship of LV Function, Transcardiac VEGF Gradient, and Coronary Blood Flow Response
The percent improvement of LV regional wall motion from 2 weeks to 6 months had a significant and positive correlation with the response of coronary blood flow to acetylcholine (5 g/min) and the transcardiac difference in VEGF levels between AIV and AO at 2 weeks (Figure 4 ) but not at 6 months (data not shown). There was also a significant correlation between the coronary blood flow response and the transcardiac VEGF gradient at 2 weeks after AMI (Figure 4) . The transcardiac gradient of TNF␣ and MCP-1 had no significant correlation with the percent improvement of LV regional wall motion and the coronary blood flow response at 2 weeks after AMI (TNF␣; rϭ0.30 and 0.28, respectively, both PϭNS. MCP-1; rϭ0.24 and 0.14, respectively, both PϭNS). 
Discussion
This study demonstrated that the impairment of epicardial dilation and increase in blood flow in response to acetylcholine of the LAD, the infarct-related coronary artery, continued until 6 months after AMI in the SES-treated patients. In contrast, the coronary responses to acetylcholine were restored to those observed in control subjects at 6 months after AMI in the BMS-treated patients. The responses of coronary diameter and blood flow to nitrate and sodium nitoprusside, endothelium-independent vasodilators, were similar among SES-and BMS-treated patients and control subjects. Thus, SES implantation may delay restoration of the reperfusion-induced endothelial vasomotor dysfunction in the large and resistance vessels of the infarct-related coronary artery compared with the BMS-treated patients. Moreover, postischemic impairment of LV regional wall motion was improved from 2 weeks to 6 months after AMI in the BMS-treated patients, whereas it did not in the SES-treated patients. Therefore, SES treatment may adversely affect the recovery of postischemic LV wall motion abnormality during the chronic phase of MI. It is known that VEGF and its receptor are expressed in the myocardium and coronary vascular bed, and that their expression is upregulated in ischemic myocardium. 18 -20 This upregulation is a compensatory mechanism to help restoration of myocardial blood flow via microvascular growth and nitric oxide-mediated vasodilation in ischemic myocardium. 19, 21, 22 Our previous 15 and present studies demonstrated that there was a step-down in VEGF levels from the AO to AIV at 2 weeks after AMI in patients with SES implantation but not in those with BMS implantation. This finding indicates that SES implantation may decrease the release of VEGF from the myocardial region supplied by the LAD. This is supported by previous reports 23 that sirolimus suppresses VEGF production in cultured cells and inhibits VEGFinduced proliferation of human endothelial cells. Also, this study showed that the transcardiac VEGF gradient (AIVϪAO VEGF levels), reflecting the VEGF levels released from myocardial region supplied by the LAD, was positively correlated with LAD endothelial vasomotor function. Therefore, the decrease in the release of VEGF from the myocardial region supplied by the LAD may play a possible role in endothelial vasomotor dysfunction in infarct-related coronary arteries treated with SES. Moreover, this study also showed that the recovery of postischemic LV dysfunction from 2 weeks to 6 months after AMI had a positive correlation with the coronary blood flow response and the transcardiac VEGF gradient at 2 weeks after AMI. This is in agreement with previous studies 6, 18, 19, 21 showing that postinfarct myocardial regeneration and remodeling may have a relationship with regional myocardial blood flow and the VEGF levels in the ischemic myocardium and coronary vascular bed. Therefore, endothelial vasomotor dysfunction and a decrease in myocardial production of VEGF during the early course of AMI may play a role in attenuating the recovery of postischemic LV dysfunction in SES-treated patients during the later phase of AMI.
It remains unclear why endothelial vasomotor dysfunction in the entire coronary tree distal to the stented segment lasted until 6 months after the stenting, because sirolimus should have completely diffused out of the stent by this time. There is a possibility that diffusion of sirolimus into coronary blood flowing through a stent may suppress VEGF release from the myocardium and endothelium of large and resistance vessels beyond the distal edge of the SES during the early phase of AMI, and this may delay the healing of reperfusion-induced endothelial injury entirely in the infarct-related coronary artery during the chronic phase of AMI. It is also possible that inflammatory cells, highly accumulated in the around of the SES struts, may release cytotoxic products including reactive oxygen species leading to inactivation of endothelium-derived nitric oxide.
Previous large cohort studies [7] [8] [9] have shown that DES implantation reduced hard end points including morbidity and mortality in any clinical setting including AMI, compared with BMS. However, this study showed that adverse effects of DES were observed on microvessel endothelial function and regional ventricular function of ischemic myocardium. It remains unknown whether these adverse effects of DES may affect morbidity and mortality, but they may potentially worse quality of life in MI survivors because of negative effects on myocardial perfusion and ventricular function. It should be noticed that the improvement of regional LV function after AMI in the BMS-treated patients was attenu- ated when patients with restenosis were included, as shown in this study. Thus, BMS also has a negative effect on recovery of postischemic LV dysfunction due to higher incidence of restenosis. 24 In this context, both SES and BMS could adversely affect the recovery of postischemic LV dysfunction through the different mechanisms, ie, endothelial dysfunction in SES and restenosis in BMS. Therefore, the potential effects of stent implantation on recovery of postischemic LV dysfunction need to be determined by the further large comparative studies of DES and BMS that include patients with restenosis.
There are several limitations in this study. The stent type was not randomized and the data are preliminary, and large randomized studies are required to confirm this data. This study examined effects of stent implantation on coronary vasomotor function after AMI in only patients without restenosis and excluded more patients with BMS than those with SES because of restenosis. This exclusion may introduce a bias for the interpretation of this data. We cannot explain for the lack of improvement of resting blood flow of the infarct-related coronary artery in spite of recovery of regional LV wall motion after AMI. Flow-wire technique and LV ventriculography may not be necessarily sensitive methods to estimate myocardial blood flow and myocardial viability in the infarct region. Other modalities such as positron emission tomography or MRI may provide more details of information regarding effects of stent types on these parameters in the infarct region. Further studies are required to elucidate the underlying mechanisms and possible influence on long-term prognosis.
In conclusion, SES implantation may delay recovery of the reperfusion-induced endothelial vasomotor dysfunction in infarct-related coronary arteries and LV dysfunction for at least 6 months after AMI in patients without restenosis. The net clinical effects need to be confirmed by further comparative studies of SES and BMS including patients with restenosis.
